Premium
O3‐03‐06: Comparison of brief cognitive tests and CSF analysis in predicting Alzheimer's disease in mild cognitive impairment: Six‐year follow‐up study
Author(s) -
Palmqvist Sebastian,
Hertze Joakim,
Minthon Lennart,
Wattmo Carina,
Blennow Kaj,
Zetterberg Henrik,
Londos Elisabet,
Hansson Oskar
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1157
Subject(s) - dementia , medicine , cerebrospinal fluid , memory clinic , cognitive impairment , vascular dementia , cognitive test , cognition , alzheimer's disease , disease , cognitive decline , oncology , psychiatry
enabling homogenous cohorts in the clinical trials reducing trial size and costs. In a proof of concept (PoC) study we identified a gene expression signature in blood that detected MCI progressing to AD (prodromal AD) in an MCI population. We have now undertaken additional studies to further investigate and develop this gene expression signature.Methods: Blood samples were obtained from the DiaGenic biobank that previously had been collected from DiaGenic’s multi-center blood collection studies in EU and the US. Total RNA was isolated from blood sampled in PAXgene“¢ tubes. Gene expression in blood was investigated using RT-qPCR on ViiA7 Dx (Life Technologies) for 384 TaqMan assays (384-assay cards) resulting in a quality approved dataset. Data modelling and analysis were performed using multivariate statistical methods. Results: In the previous PoC study we developed the first blood based prodromal AD gene expression biomarker based on an algorithm (model) using the gene expression information from 20 assays to predict MCI progressing to AD in an MCI population. The prediction accuracy of detecting prodromal AD was 74%, sensitivity 74% and specificity 75%. Now we present new results from additional studies on developing and evaluating this gene expression signature for prodromal AD.Conclusions:We have demonstrated that it is possible to detect individuals with MCI progressing to AD (prodromal AD) within 2 years from AD diagnosis based on analysis of gene expression in blood. The new results will increase our understanding of the utility of this potential diagnostic biomarker for prodromal AD.